iRadimed (NASDAQ:IRMD) Sees Strong Trading Volume – What’s Next?

iRadimed Corporation (NASDAQ:IRMD) shares saw an uptick in trading volume on Wednesday . 48,762 shares were traded during trading, a decline of 45% from the previous session’s volume of 88,590 shares.The stock last traded at $88.7150 and had previously closed at $87.36.

Analyst Ratings Changes

A number of research firms have weighed in on IRMD. Roth Mkm reissued a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Stock Performance

The company has a 50 day moving average price of $92.91 and a 200 day moving average price of $95.13. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 50.91 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, research analysts forecast that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s dividend payout ratio is 43.72%.

Insider Activity

In related news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $87.88, for a total value of $219,700.00. Following the sale, the chief executive officer owned 2,172,500 shares in the company, valued at approximately $190,919,300. The trade was a 0.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 67,500 shares of company stock valued at $6,318,853. 36.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On iRadimed

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of iRadimed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after buying an additional 5,475 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after buying an additional 205,783 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock valued at $21,768,000 after buying an additional 9,017 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after buying an additional 55,426 shares during the period. Finally, State Street Corp raised its holdings in shares of iRadimed by 3.1% in the 4th quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock valued at $18,770,000 after buying an additional 5,713 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.